---
title: "SinoMab Clarifies Use of 2025 Share Proceeds and Share Award Details"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299440518.md"
description: "SinoMab Bioscience clarified that net proceeds from its May and July 2025 share subscriptions were used as intended. Additionally, the company reported that 1,220,000 share awards vested, with 85,000 exercised at HK$1.12 per share. The rest of the annual report remains unchanged."
datetime: "2026-09-18T11:12:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299440518.md)
  - [en](https://longbridge.com/en/news/299440518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299440518.md)
generator: "portal-rs"
---

# SinoMab Clarifies Use of 2025 Share Proceeds and Share Award Details

SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.

SinoMab BioScience has issued a supplemental announcement to its 2025 Annual Report, clarifying how it deployed funds raised from two share subscription exercises completed in May and July 2025 under a general mandate. The company confirmed that the net proceeds from both subscriptions were used in line with previously disclosed intentions, reinforcing its adherence to stated capital allocation plans and providing additional transparency for shareholders.

The company also elaborated on its share-based incentives, stating that 1,220,000 awards under its Share Award Scheme vested during the reporting period and are classified as share options under relevant accounting standards. Of these, 85,000 options were exercised at HK$1.12 per share, with a weighted average closing price of HK$1.69 before exercise, while the rest of the annual report remains unchanged, indicating no broader revisions to its previously reported financials or governance disclosures.

**More about SinoMab Bioscience Ltd.**

SinoMab BioScience Limited is a Hong Kong-incorporated biopharmaceutical company listed on the Stock Exchange of Hong Kong, focusing on the research, development and commercialization of innovative biologic therapies. The company operates in the biotechnology and life sciences sector and funds its pipeline and operations through equity financing and share-based incentive schemes.

**Average Trading Volume:** 1,585,659

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$1.55B

For a thorough assessment of 3681 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [03681.HK](https://longbridge.com/en/quote/03681.HK.md)

## Related News & Research

- [SinoMab BioScience held shareholder meeting, disposal resolution drew 100% support](https://longbridge.com/en/news/298192293.md)
- [SinoMab BioScience announces extraordinary general meeting](https://longbridge.com/en/news/296540884.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**